Amgen (AMGN) - Options Trading Review

Posted on 01/17/2013 by Allen Bersch

Share on StockTwits

NEW YORK (AVAFIN) -- Amgen witnessed a record number of call and put contracts during the busy trading session. There were 0.6 call contracts traded for each put contract yielding a 1.72 put/call ratio where 11,482 put and 6,668 call contracts exchanged hands.

View Options Trading Activities

Put/Call ratio is often used to measure investor sentiment, the ratio serves as a predictor of investor behavior. A high put/call ratio suggests that the investor sentiment is bearish and that investors expect the underlying stock to decrease in value. In contrast, a low put/call ratio suggests that the investor sentiment is bullish and that the underlying stock is expected to increase in value. Unusual volume provides reliable clues that the stock is expected to make a move.

The trading volume of 6M is above the 90 day average volume of 4M shares. Shares of Amgen edged down $0.38 (0.45%) to $83.94. The price of the stock ranged between a low of $83.88 and $84.47 respectively.

View Best Performing Stocks

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and received approval for bone-strengthening drug Prolia/Xgeva in 2010.


:: Market Movers ::

:: Technical Alerts ::

:: Candle Stick Alerts ::

:: Chart Patterns ::

:: Options Advisory Center ::

:: Block Trades Review ::

:: Trade Flow Analysis ::